The two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination and if appropriate, may conduct further development exploring the potential role of this regimen in the treatment of metastatic melanoma.
“We have made significant progress in treating metastatic melanoma and hope to further improve outcomes by combining two agents that target this deadly disease in different ways,” said Hal Barron M.D., chief medical officer and head, Global Product Development, Roche. “We look forward to working with BMS in this ground-breaking collaboration to explore new options for patients.”
“Metastatic melanoma is one of the most aggressive forms of cancer,” said Brian Daniels, senior vice president of Development and Medical Affairs, BMS. “We are excited to be working with Roche to evaluate the potential that together YERVOY and vemurafenib could improve outcomes for melanoma patients.”